 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or [0m
[34mdecrease the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or [0m
[32mdecrease the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ALENDRONATE SODIUM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE SODIUM: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the [0m
[31mbone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled [0m
[31mduring bone turnover. Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of [0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. ALENDRONATE SODIUM: pharmacodynamics: These changes[0m
[31mresult in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to [0m
[31mage [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mALENDRONATE SODIUM: pharmacodynamics: Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent [0m
[31minhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. [0m
[31mThese biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. [0m
[31mLong-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides [0m
[31mof type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. ALENDRONATE SODIUM: pharmacodynamics: Similar decreases were seen [0m
[31min patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m
[31mto [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of [0m
[31mbone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In [0m
[31mosteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: pregnancy: The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of [0m
[31madministration [0m[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All [0m
[31mpregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in [0m
[31mclinically recognized pregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased [0m
[31mpostimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, [0m
[31mmg/m [0m[1;31m2[0m[31m . ALENDRONATE SODIUM: pregnancy: Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m [0m
[31mmg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to [0m
[31mapproximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical [0m
[31mdaily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m [0m
[31mmg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: pregnancy: Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in[0m
[31mthe drinking water or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. [0m
[31mHowever, intravenous calcium supplementation prevented maternal, but not neonatal deaths.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: use_in_specific_populations: Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased [0m
[31mpostimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, [0m
[31mmg/m [0m[1;31m2[0m[31m . Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times [0m
[31mthe [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg [0m
[31mclinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m
[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation [0m
[31mstarting at [0m[1;31m0.5[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m
[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking [0m
[31mwater or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE [0m
[31mSODIUM: use_in_specific_populations: However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present[0m
[31min human breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's [0m
[31mclinical need for BINOSTO and any potential adverse effects on the breastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in [0m
[31mpediatric patients. The safety and efficacy of alendronate sodium were examined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe[0m
[31mosteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg [0m
[31malendronate sodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD [0m
[31mZ-score from baseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the alendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen [0m
[31mpercent of the alendronate-treated patients who sustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when [0m
[31massessed radiographically at Month [0m[1;31m24[0m[31m compared with [0m[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE SODIUM: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data [0m
[31mobtained at Month [0m[1;31m24[0m[31m demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between [0m
[31mthe alendronate sodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in [0m
[31mosteogenesis imperfecta patients treated for up to [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of [0m
[31mvomiting in osteogenesis imperfecta patients treated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with[0m
[31malendronate sodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m patients treated with placebo.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or [0m
[32mdecrease the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE SODIUM: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the [0m
[31mbone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled [0m
[31mduring bone turnover. Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of [0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. ALENDRONATE SODIUM: pharmacodynamics: These changes[0m
[31mresult in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to [0m
[31mage [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mALENDRONATE SODIUM: pharmacodynamics: Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent [0m
[31minhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. [0m
[31mThese biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. [0m
[31mLong-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides [0m
[31mof type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. ALENDRONATE SODIUM: pharmacodynamics: Similar decreases were seen [0m
[31min patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m
[31mto [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of [0m
[31mbone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In [0m
[31mosteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: pregnancy: The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of [0m
[31madministration [0m[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All [0m
[31mpregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in [0m
[31mclinically recognized pregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased [0m
[31mpostimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, [0m
[31mmg/m [0m[1;31m2[0m[31m . ALENDRONATE SODIUM: pregnancy: Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m [0m
[31mmg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to [0m
[31mapproximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical [0m
[31mdaily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m [0m
[31mmg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: pregnancy: Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in[0m
[31mthe drinking water or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. [0m
[31mHowever, intravenous calcium supplementation prevented maternal, but not neonatal deaths.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: use_in_specific_populations: Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased [0m
[31mpostimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, [0m
[31mmg/m [0m[1;31m2[0m[31m . Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times [0m
[31mthe [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg [0m
[31mclinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m
[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation [0m
[31mstarting at [0m[1;31m0.5[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m
[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking [0m
[31mwater or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE [0m
[31mSODIUM: use_in_specific_populations: However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present[0m
[31min human breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's [0m
[31mclinical need for BINOSTO and any potential adverse effects on the breastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in [0m
[31mpediatric patients. The safety and efficacy of alendronate sodium were examined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe[0m
[31mosteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg [0m
[31malendronate sodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD [0m
[31mZ-score from baseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the alendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen [0m
[31mpercent of the alendronate-treated patients who sustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when [0m
[31massessed radiographically at Month [0m[1;31m24[0m[31m compared with [0m[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE SODIUM: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data [0m
[31mobtained at Month [0m[1;31m24[0m[31m demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between [0m
[31mthe alendronate sodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in [0m
[31mosteogenesis imperfecta patients treated for up to [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of [0m
[31mvomiting in osteogenesis imperfecta patients treated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with[0m
[31malendronate sodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m patients treated with placebo.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or [0m
[32mdecrease the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does alendronate sodium have any effect on the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes alendronate sodium have any effect [0m
[32mon the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes alendronate sodium have any effect on the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does alendronate sodium have any effect on the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"alendronate sodium"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE SODIUM: pregnancy: The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of [0m
[31madministration [0m[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All [0m
[31mpregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in [0m
[31mclinically recognized pregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased [0m
[31mpostimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, [0m
[31mmg/m [0m[1;31m2[0m[31m . ALENDRONATE SODIUM: pregnancy: Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m [0m
[31mmg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to [0m
[31mapproximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical [0m
[31mdaily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m [0m
[31mmg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: pregnancy: Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in[0m
[31mthe drinking water or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. [0m
[31mHowever, intravenous calcium supplementation prevented maternal, but not neonatal deaths.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: clinical_studies: [0m[1;31m14[0m[31m CLINICAL STUDIES [0m[1;31m14.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO [0m[1;31m([0m[31malendronate sodium[0m[1;31m)[0m[31m effervescent tablet [0m[1;31m70[0m[31m mg is bioequivalent to [0m
[31malendronate sodium tablet [0m[1;31m70[0m[31m mg. The fracture reduction efficacy and bone mineral density changes attributed to BINOSTO are based on clinical trial data of alendronate sodium [0m[1;31m10[0m[31m mg daily and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg weekly. Daily Dosing The efficacy of alendronate sodium [0m[1;31m10[0m[31m mg daily was assessed in four clinical trials. Study [0m[1;31m1[0m[31m, a three-year, multicenter double-blind, placebo-controlled, [0m
[31mUS clinical study enrolled [0m[1;31m478[0m[31m patients with a BMD T-score at or below minus [0m[1;31m2.5[0m[31m with or without a prior vertebral fracture; Study [0m[1;31m2[0m[31m, a three-year, multicenter double blind placebo controlled [0m
[31mMultinational clinical study enrolled [0m[1;31m516[0m[31m patients with a BMD T-score at or below minus [0m[1;31m2[0m[31m. ALENDRONATE SODIUM: clinical_studies: [0m[1;31m5[0m[31m with or without a prior vertebral fracture; Study [0m[1;31m3[0m[31m, the Three-Year [0m
[31mStudy of the Fracture Intervention Trial [0m[1;31m([0m[31mFIT[0m[1;31m)[0m[31m a study which enrolled [0m[1;31m2027[0m[31m postmenopausal patients with at least one baseline vertebral fracture; and Study [0m[1;31m4[0m[31m, the Four-Year Study of FIT: a study which[0m
[31menrolled [0m[1;31m4432[0m[31m postmenopausal patients with low bone mass but without a baseline vertebral fracture. Effect on Fracture Incidence To assess the effects of alendronate sodium on the incidence of [0m
[31mvertebral fractures [0m[1;31m([0m[31mdetected by digitized radiography; approximately one third of these were clinically symptomatic[0m[1;31m)[0m[31m, the U.S. and Multinational studies were combined in an analysis that compared [0m
[31mplacebo to the pooled dosage groups of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m or [0m[1;31m10[0m[31m mg for three years or [0m[1;31m20[0m[31m mg for two years followed by [0m[1;31m5[0m[31m mg for one year[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: clinical_studies: There was a [0m
[31mstatistically significant reduction in the proportion of patients treated with alendronate experiencing one or more new vertebral fractures relative to those treated with placebo [0m[1;31m([0m[1;31m3.2[0m[31m% vs. [0m[1;31m6.2[0m[31m%; a [0m[1;31m48[0m[31m%[0m
[31mrelative risk reduction[0m[1;31m)[0m[31m. A reduction in the total number of new vertebral fractures [0m[1;31m([0m[1;31m4.2[0m[31m vs. [0m[1;31m11.3[0m[31m per [0m[1;31m100[0m[31m patients[0m[1;31m)[0m[31m was also observed. In the pooled analysis, patients who received alendronate had a [0m
[31mloss in stature that was statistically significantly less than was observed in those who received placebo [0m[1;31m([0m[1;31m-3.0[0m[31m mm vs. [0m[1;31m-4.6[0m[31m mm[0m[1;31m)[0m[31m. The Fracture Intervention Trial [0m[1;31m([0m[31mFIT[0m[1;31m)[0m[31m consisted of two studies in [0m
[31mpostmenopausal women: the Three-Year Study of patients who had at least one baseline radiographic vertebral fracture and the Four-Year Study of patients with low bone mass but without a baseline [0m
[31mvertebral fracture. In both studies of FIT, [0m[1;31m96[0m[31m% of randomized patients completed the studies [0m[1;31m([0m[31mi.e. ALENDRONATE SODIUM: clinical_studies: had a closeout visit at the scheduled end of the study[0m[1;31m)[0m[31m; [0m
[31mapproximately [0m[1;31m80[0m[31m% of patients were still taking study medication upon completion. Fracture Intervention Trial: Three-Year Study [0m[1;31m([0m[31mpatients with at least one baseline radiographic vertebral fracture[0m[1;31m)[0m[31m [0m
[31mThis randomized, double-blind, placebo-controlled, [0m[1;31m2027[0m[31m-patient study [0m[1;31m([0m[31malendronate, [0m[31mn[0m[31m=[0m[1;31m1022[0m[31m; placebo, [0m[31mn[0m[31m=[0m[1;31m1005[0m[1;31m)[0m[31m demonstrated that treatment with alendronate sodium resulted in statistically significant [0m
[31mreductions in fracture incidence at three years as shown in Table [0m[1;31m4[0m[31m. ALENDRONATE SODIUM: clinical_studies: Table [0m[1;31m4[0m[31m Effect of Alendronate Sodium on Fracture Incidence in the Three-Year Study of FIT [0m
[1;31m([0m[31mPatients With Vertebral Fracture at Baseline[0m[1;31m)[0m[31m Percent of Patients Alendronate Sodium [0m[1;31m([0m[31mN = [0m[1;31m1022[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mN = [0m[1;31m1005[0m[1;31m)[0m[31m Absolute Reduction in Fracture Incidence Relative Reduction in Fracture Risk % [0m
[31mPatients with: Vertebral fractures [0m[1;31m([0m[31mdiagnosed by X-ray[0m[1;31m)[0m[31m Number evaluable for vertebral fractures: alendronate, [0m[31mn[0m[31m=[0m[1;31m984[0m[31m; placebo, [0m[31mn[0m[31m=[0m[1;31m966[0m[31m ≥[0m[1;31m1[0m[31m new vertebral fracture [0m[1;31m7.9[0m[31m [0m[1;31m15.0[0m[31m [0m[1;31m7.1[0m[31m [0m[1;31m47[0m[31m p<[0m[1;31m0.001[0m[31m, ≥[0m[1;31m2[0m[31m new vertebral[0m
[31mfractures [0m[1;31m0.5[0m[31m [0m[1;31m4.9[0m[31m [0m[1;31m4.4[0m[31m [0m[1;31m90[0m[31m Clinical [0m[1;31m([0m[31msymptomatic[0m[1;31m)[0m[31m fractures Any clinical [0m[1;31m([0m[31msymptomatic[0m[1;31m)[0m[31m fracture [0m[1;31m13.8[0m[31m [0m[1;31m18.1[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m26[0m[31m [0m[31mp[0m[31m=[0m[1;31m0[0m[31m. ALENDRONATE SODIUM: clinical_studies: [0m[1;31m007[0m[31m, ≥[0m[1;31m1[0m[31m clinical [0m[1;31m([0m[31msymptomatic[0m[1;31m)[0m[31m vertebral [0m
[31mfracture [0m[1;31m2.3[0m[31m [0m[1;31m5.0[0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m54[0m[31m p<[0m[1;31m0.01[0m[31m, Hip fracture [0m[1;31m1.1[0m[31m [0m[1;31m2.2[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m51[0m[31m p<[0m[1;31m0.05[0m[31m Wrist [0m[1;31m([0m[31mforearm[0m[1;31m)[0m[31m fracture [0m[1;31m2.2[0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m48[0m[31m Furthermore, in this population of patients with baseline vertebral fracture, treatment with [0m
[31malendronate sodium significantly reduced the incidence of hospitalizations [0m[1;31m([0m[1;31m25.0[0m[31m% vs. [0m[1;31m30.7[0m[31m%[0m[1;31m)[0m[31m. In the Three-Year Study of FIT, fractures of the hip occurred in [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m2.2[0m[31m%[0m[1;31m)[0m[31m of [0m[1;31m1005[0m[31m patients on placebo and[0m
[1;31m11[0m[31m [0m[1;31m([0m[1;31m1.1[0m[31m%[0m[1;31m)[0m[31m of [0m[1;31m1022[0m[31m patients on alendronate sodium, [0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.047[0m[31m. Figure [0m[1;31m1[0m[31m displays the cumulative incidence of hip fractures in this study.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: use_in_specific_populations: Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased [0m
[31mpostimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, [0m
[31mmg/m [0m[1;31m2[0m[31m . Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times [0m
[31mthe [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg [0m
[31mclinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m
[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation [0m
[31mstarting at [0m[1;31m0.5[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m
[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking [0m
[31mwater or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE [0m
[31mSODIUM: use_in_specific_populations: However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present[0m
[31min human breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's [0m
[31mclinical need for BINOSTO and any potential adverse effects on the breastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in [0m
[31mpediatric patients. The safety and efficacy of alendronate sodium were examined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe[0m
[31mosteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg [0m
[31malendronate sodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD [0m
[31mZ-score from baseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the alendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen [0m
[31mpercent of the alendronate-treated patients who sustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when [0m
[31massessed radiographically at Month [0m[1;31m24[0m[31m compared with [0m[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE SODIUM: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data [0m
[31mobtained at Month [0m[1;31m24[0m[31m demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between [0m
[31mthe alendronate sodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in [0m
[31mosteogenesis imperfecta patients treated for up to [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of [0m
[31mvomiting in osteogenesis imperfecta patients treated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with[0m
[31malendronate sodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m patients treated with placebo. ALENDRONATE SODIUM: use_in_specific_populations: In a pharmacokinetic study, [0m[1;31m6[0m[31m of [0m[1;31m24[0m[31m pediatric osteogenesis imperfecta patients who [0m
[31mreceived a single oral dose of alendronate sodium [0m[1;31m35[0m[31m or [0m[1;31m70[0m[31m mg developed fever, flu-like symptoms, and/or mild lymphocytopenia within [0m[1;31m24[0m[31m to [0m[1;31m48[0m[31m hours after administration. These events, lasting no more [0m
[31mthan [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m days and responding to acetaminophen, are consistent with an acute-phase response that has been reported in patients receiving bisphosphonates, including alendronate sodium. [0m[1;31m[[0m[31mSee Adverse [0m
[31mReactions [0m[1;31m([0m[1;31m6.2[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m8.5[0m[31m Geriatric Use Of the patients receiving alendronate sodium in the Fracture Intervention Trial [0m[1;31m([0m[31mFIT[0m[1;31m)[0m[31m, [0m[1;31m71[0m[31m% [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2302[0m[1;31m)[0m[31m were greater than or equal to [0m[1;31m65[0m[31m years of age and [0m[1;31m17[0m[31m% [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m550[0m[1;31m)[0m[31m [0m
[31mwere greater than or equal to [0m[1;31m75[0m[31m years of age.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress [0m
[31mosteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In[0m
[31maddition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone [0m
[31mhydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process[0m
[31mis ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is [0m
[31mcharacterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of low bone mass, evidence of fracture on x-ray, a history of osteoporotic [0m
[31mfracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females but is most common among women following the menopause, when bone [0m
[31mturnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m
[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m
[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE SODIUM: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or more osteoporosis-related fractures of the spine, hip, or [0m
[31mwrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for[0m
[31msix weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen [0m
[31mdegradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the [0m
[31mdiscontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m [0m
[31mmg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively,[0m
[31mto reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease [0m
[31min the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with [0m
[31malendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific [0m
[31malkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate [0m
[31msodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal [0m
[31mwomen during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the treatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data [0m
[31mindicate that the rate of bone turnover reached a new steady state, despite the progressive increase in the total amount of alendronate deposited within bone.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE SODIUM does not contain information regarding its effect on mortality risk after myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE SODIUM does not contain information regarding its effect on mortality risk after myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE SODIUM increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE SODIUM does not contain information regarding its effect on mortality risk after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback [0m
[31mwas provided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ALENDRONATE SODIUM does not contain information regarding its effect on mortality risk after myocardial infarction. Therefore, it is not possible to determine from this data whether [0m
[32mALENDRONATE SODIUM increases or decreases the risk of mortality after myocardial infarction.[0m
